Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Melanoma, Cutaneous Malignant 1 Glioblastoma 1 Colonic Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Dexamethasone 33 Cyclophosphamide 31 fludarabine 19 venetoclax 18 Lenalidomide 16 Bortezomib 16 Cytarabine 13 pembrolizumab 12 Calcium Dobesilate 12 Carboplatin 11 fludarabine phosphate 10 Rituximab 10 pomalidomide 9 Gemcitabine 9 Nivolumab 8 Azacitidine 7 daratumumab 6 carfilzomib 6 blinatumomab 6 Decitabine 6 Bendamustine Hydrochloride 6 selinexor 5 obinutuzumab 5 ibrutinib 5 Vincristine 5 Temozolomide 5 Methotrexate 5 Etoposide 5 Cisplatin 5 tafasitamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × nintedanib × Clear all

NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡